Demam Berdarah Dengue dan Perkembangan Vaksinnya (Studi Pustaka) - MCUrepository
DAFTAR PUSTAKA
Almond l Clemens l, Engel's H, Halstead S., Khiem HR, Pabloz-Mendez A, et
al. 2002. Accelerating the development and introduction of dengue vaccine
fool' poor children, 5-8 December 2001, Ho Chi Minh City, VietNam.
Vaccine, 20: p. 3043-3046.
Amin P., Bhandare S., and Srivastava A 2001. Dengue, Dengue Haemorrhagic
Fever,
Dengue
Shock
Syndrome.
http://www.bl1i.orQ.!journal/200I 4303 iulvOlircvicw 380.11t111
27-04-2004.
Anderson R, Wang S., Osiowy C. and Issekutz AC. 1997. Activation
Endothelial Cells via Antibody-enhanced
Dengue Virus infection
Peripheral Blood Monocytes. 1. Virol., 71 (6): p. 4226-4232.
Anna
of
of
Durbin,
Phase
I
3] 9642BSC64CBEB
http://c linicaltrials. gOY!ct{Q.ui!infilipharu~ssjonid=269
7BFAB09B4BB133, 9 ok'1ober2004).
Bancroft W.R., Top, Jr F.R., Eckels K.H, Anderson, Jr. lH, McCown lM., and
Russell P.K. 1981. Dengue-2 vaccine: virological, immunological, and
clinical responses of six yellow fever-immune recipients. l1?fect Immlln., 31
(2): p. 698-703.
Bhamarapravati N. and Y oksan S. 1997. Live attenuated tetravalent dengue
vaccine. In DJ. Gubler and G. Kune: Dengue and Dengue Hemorrhagic
Fever. Cambridge: University press. p. 367-377.
. 2000.
44-47.
Live attenuated tetravalent dengue vaccine. Vaccine, 18 (2): p.
Blaney lE. Jr, Manipon G.G., Firestone c.Y, Johnson D.H, Hanson c.T.,
Murphy RR, et al. 2003. Mutations which enhance the replication of
dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine
candidate in Vero cells. Vaccine, 21 (27-30): p. 4317-27.
Blaney Jr lE., Johnson D.H, Firestone c.Y, Hanson C.T., Murphy B.R, and
Whitehead S.S. 2001. Chemical Mutagenesis of Dengue Virus Type
4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or
Human Liver Cells and Attenuated in Mice. Journal of Virology, 75 (20): p.
9731-40.
Bosch I., Xhaja K., Estevez L., Raines G., Melichar H, Warke RY., et al. 2002.
Increased Production of Interleukin-8 in Primary Human Monocytes and in
134
135
Human Epithelial and Endothelial Cell Lines after Dengue Virus Challenge.
Journal of Virology, 76 (11): p. 5588-5597.
Bosch 1. 2003. Gene Expression of Host Cells Infected with Dengue Virus.
http://\yww.ipk .sId. cui curSO-Q~l}gUCmemoria s/confcrcncias- roam stralc s/23. pdf
,28-01-2005.
Bray M., Men R., and Lai C.I. 1996. Monkeys immunized with intertypic
chimeric dengue viruses are protected against wild-type virus challenge. J
Virol., 70 (6): p. 4162-4166.
Bumi c., Rantam F.A, Soegijanto S., dan Hamid 1.S. 2004. Determinan virulensi
virus dengue. In Soegeng Soegijanto: Demam berdarah dengue: tiryauan
OOn temuan bam di era 2003. Surabaya: Airlangga University Press. p. 9197.
Catteau A, Roue G., Yuste V.I., Susin S.A, and Despres P. 2003. Expression of
dengue ApoptoM sequence results in disruption of mitochondrial potential
and caspase activation. Biochimie, 85 (8): pp. 789-793.
CDS.1999. Regional guidenesson Dengue/DHF prevention
http://ww\v.org/whosea/cds!index.htl11 , 13-] 0-2004.
and
control.
Cella M., Salio M., Sakakibara Y, Langen R., Julkllnen 1., and Lanzavecchia A
1999. Maturation, activation, and protection of dendritic cells induced by
double stranded RNA J Exp. Med, 189 (5): p. 821-829.
Chambers T.I., Liang Y, Droll D.A, Schlesinger J.J, Davidson AD., Wright PJ.,
et al. 2003. Yellow Fever Virus/Dengue-2
Virus and Yellow Fever
Virus/Dengue-4
Virus
Chimeras:
Biological
Characterization,
Immunogenicity, and Protection against Dengue Encephalitis in the Mouse
Model. Journal of Virology, 77 (6): p. 3655-3668.
Chang D.M. and Shaio M.F.1994. Production of interleukin-l (lL-l) and lL-l
inhibitor by human monocytes exposed to dengue virus. Journal of
Infectious Diseases, 170 (4): pp. 811-817.
Chang G.J. 1997. Molecular biology of dengue viruses. In DJ. Gubler and G.
Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University
press. p. 175-198.
Chang G.I., Kuno G., Purdy D.E., and Davis B.S. 2004. Recent advancement
flavivirus vaccine development. Expert Rev 'Vaccines., 3 (2): p. 199-220.
in
Chang HH., Shyu H.F., Wang YM., Sun D.S., Shyu RH, Tang S.S., et al. 2002.
Facilitation of cell adhesion by immobilized dengue viral non structural
136
protein 1 (NS1): Arginine-glycine-aspartic acid structural mimicry within
the dengue viral NS 1 antigen. Journal of ltifectious Diseases, ] 86 (6): pp.
743-751.
Chao D.Y, Lin T.H., Hwang KP., Huang J.H., Liu c.c., and King C.C.1998.
dengue
hemoIThagic
fever
epidemic
in
Taiwan.
L/'iDV\\'..~d_~£QyincidO(EEfJ)Iy_ol1 Ono3/0_~::(L'J_~htm,
27-04-2004.
Chaturvedi u.c., Elbishbishi E.A, Agarwal R, and Mustafa AS. 2001. Cytotoxic
factor-autoantibodies: possible role in the pathogenesis of dengue
haemorrhagic fever FEMS. Immunology & Medical Microbiology, 30 (3):
pp. 181-186.
Chen yc. and Wang S.Y 2002. Activation of Terminally Differentiated Human
Monocytes/Macrophages
by Dengue Virus: Productive Infection,
Hierarchical Production of Innate Cytokines and Chemokines, and the
Synergistic Effect of Lipopolysaccharide. Journal of Virology, 76 (19): p.
9877-9887.
Chen YP., Maguire T., Hileman RE., Fromm J.R, Esko J.D., Linhardt RJ. et a1.
1997. Dengue virus infectivity depends on envelope protein binding to target
cel1 heparan sulfate. Nature Medicine, 3 (8): p. 866-871.
Chung N.P.Y, Chen Y, Chan V.S.F., TAM P.KH., and Lin c.L.S. 2004.
Dendritic cells: sentinels against pathogens. Histology and Histopathology,
]9 (1): p. 317-314.
Chungue E., Poli L., Roche c., Gestas P., Glaziou P., and Markoff LJ. 1994.
Correlation between detection of plasminogen cross-reactive antibodies and
hemorrhage in dengue virus infection. J l1ifect Dis., 170 (5): p. ] 304-7.
Craig S., Myat Thu H., Lowry K, Wang x.F., Holmes E.C., and Aaskov J. 2003.
Diverse dengue type 2 virus population contain recombinant and both
parental viruses in a single mosqiuto host. Journal of T'irology, 77 (7): p.
4463-4467.
Diamond M.S., Edgil D., Roberts T.G., Lu B., and Harris E. 2000. Infection of
Human Cel1s by Dengue Virus Is Modulated by Different Cel1 Types and
Viral Strains. Journal ofTTirology, 74 (17): p. 7814-7823.
Dos Santos F.B., Miagostovich M.P., Noguiera M.R, Schatmayr H.G., Riley
L.W., Harris E. Analysis of recombinant Dengue virus polypeptides for
Dengue diagnosis ang evaluation of the humoral immune response. Am. 1.
Trop. A1ed. Hyg., 71(2): pp. ]44-]52
137
Durbin AP., Karron RA, Sun W., Vaughn D.W., Reynolds M.l, Perreault lR,
et aI. 200]. Attenuation and Immunogenecity in Humans of Live Dengue
Virus type-4 Vaccine Candidate with 30 Nucleotide Deletion in its 3'Untranslated Region. Am. J Trop. Med. Hyg., 65 (5): p. 405-413.
Eckels KH. and Putnak R 2003. Formalin-inactivated whole virus and
recombinant subunit flavivirus vaccines. Adv Vims Res, 61: p. 395-418.
Eckels KH., Scott RM., Bancroft W.H., Brown l, Dubois D.R, Summers P.L.,
et al. ] 984. Selection of attenuated dengue 4 viruses by serial passage in
primary kidney cells. V. Human response to immunization with a candidate
vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg., 33 (4): p.
684-9.
Edelman R, Wasserman S.S., Bodison S.A, Putnak R.l, Eckels KH., Tang D., et
al. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated
dengue vaccine. Am J TropMed Hyg., ;69(6 Suppl):48-60.
Espina L.M., Valero N.J., Hernandez lM., and Mosquera lA 2003. Increased
apoptosis and expresion of tumor necrosis factor a caused by infection of
cultured of human monocytes with dengue virus. Am. J Trop. Med. Hyg., 68
(1): p. 48-53.
Gagnon S.J., Ennis F.A, and Rothman AL. ]999. Bystander Target Cell Lysis
and Cytokine Production by Dengue Virus-Specific Human CDr Cytotoxic
T-Lymphocyte Clones. Journal of Virology, 73 (5): p. 3623-3629.
Gagnon S.J., Mori M., Kurane I., Green S., Vaughn D.W., Kalayanarooj S., et al.
2002. Cytokine gene expression and protein production in peripheral blood
mononuclear cells of children with acute dengue virus infections. J Med
Virol, 67 (1): p. 4]-6.
Green
S., Vaughn D.W., Kalayanarooj S., Nimmannitya
S., Suntayakorn S.,
]
Nisalak A, et al. 999. Early Immune Activation in Acute Dengue Illness Is
Related to Development
of Plasma Leakage and Disease Severity.
The Journal
£?!Infectious
Diseas'es,
] 79: p. 755-762.
Green S., Kurane I., Edelman R, Tacket CO, Eckels KH., Vaughn D.W., Hoke
Jr CH., and Ennis F.A 1993. Dengue virus-specific human CD4+ Tlymphocyte responses in a recipient of an experimental live-attenuated
dengue virus type ] vaccine: bulk culture proliferation, clonal analysis, and
precursor frequency determination. J Virol., 67 (10): p. 5962-67.
Gubler D.J. 1998. Dengue and dengue hemorrhagic fever. Clinical Microbiology
Reviews, 11(3): p. 480-496.
138
Guirakhoo F., Arroyo 1., Pugachev KY., Miller c., Zhang Z.X, Weltzin R, et al.
2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of a
Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. Journal of
Virology, 75 (16): p. 7290-7304.
Guirakhoo F., Pugachev K, Arroyo 1., Miller c., Zhang Z.X, Weltzin R, et al.
2002. Viremia and immunogenicity in nonhuman primates of a tetravalent
yellow fever-denbrue chimeric vaccine: genetic reconstructions, dose
adjustment, and antibody responses against wild-type dengue virus isolates.
Virology, 298 (1): p. 146-59.
Guirakhoo F., Pugachev K, Zhang Z., Myers G., Levenbook 1., Draper K,et aI.
2004.
Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus
Tetravalent Vaccine Formulations
in Nonhuman Primates. Journal qf
Virology, 78 (9): p. 4761-4775
Guirakhoo
F., Weltzin R, Chambers TJ., Zhang Z.X,
Soike K, Ratterree M.,.
Arroyo 1., et aI. 2000. Recombinant Chimeric Yellow Fever-Dengue Type
2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal of
Virology, 74 (12): p. 5477-5485.
Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K, Nichols
2004. A single amino acid substitution in the envelope protein of
yellow fever-dengue 1 vaccine virus reduces neurovirulence for
mice and viremia/viscerotropism
for monkeys. J Virol., 78 (18):
10008.
Guzman M.G. 1998. Advances in the development
Acta Cient Venez., 49 Suppl 1: p. 38-45
R, et aI.
chimeric
suckling
p. 9998-
of a vaccine against dengue.
Guzman M.G., Rodriguez R, Rodriguez R, Hennida L., Alvarez M., Lazo L., et
aI. 2003. Induction of neutralizing antibodies and partial protection fron viral
challengge in Macaca Fascicularis immunized with recombinant Dengue 4
virus envelope gycoprotein expressed in Pischia pastoris .Am. 1. Trap. Med
Hyg., 69 (2): p. 129-134.
Gwinn W., Sun W., Innis B.L., Caudill 1., and King AD. 2003. Serotype-specific
TH1 responses in recipients of two doses of candidate live-attenuated
dengue virus vaccines. American Journal of Tropical Medicine & Hygiene,
69 (6): p. 39-47 (SuppI. S).
Hadinegoro
A,RH.,
Soegijanto S., Wuryahadi S., dan Suroso T. 1998.
Tatalaksana demam dengue/demam berdarah dengue pada anak. In Sri
Rezeki H. Hadinegoro dan Hindra Irawan Satari: Demam berdarah dengue.
Jakarta: FKUI. p. 82-84.
139
Halstead S.B. 1988. Pathogenesis of dengue: challenges to molecular biology.
Science, 239 (4839): p. 476-81.
Halstead S.B. 1997. Epidemiology of dengue and dengue hemorrhagic fever. In
D.1. Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever.
Cambridge: University press. p. 23-44.
Halstead S.B. and Marchette N.1. 2003. Biologic properties of dengue viruses
following serial passage in primary dog kidney cells: Studies at the
University of Hawaii. American Journal of Tropical Medicine & Hygiene,
69 (6): pp. 5-11 (Supp!. S).
Hanley KA., Manlucu L.R, Manipon G.G., Hanson C.T., Whitehead S.S.,
Murphy B.R, et a!. 2004. Introduction of mutations into the non-structural
genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine
candidate further decreases replication in rhesus monkeys while retaining
protective immunity. Vaccine, 22 (25-26): p. 3440-8.
Hanley KA., Lee J.1., Blaney, Jr lE., Murphy B.R., and Whitehead S.S. 2002.
Paired Charge-to-Alanine
Mutagenesis of Dengue Virus Type 4 NS5
Generates Mutants with Temperature-Sensitive,
Host Range, and Mouse
Attenuation Phenotypes. Journal (if Virology, 76 (2): p. 525-531.
Harrison V.R, Eckels KH., Sagartz lW., and Russell P.K 1977. Virulence and
immunogenicity of a temperature-sensitive dengue-2 virus in lower
primates. Infect Immull.,18 (1): p. 151-6.
Henke A. 2002. DNA immunization--a new chance in vaccine research? Med
A1icrobiollmmunol (Berl)., 191 (3-4): p. 187-90.
Ho L.1., Wang J.1., Shaio M.F., Kao c.L., Chang D.M., Han S.W., et a!. 2001.
Infection of human dendritic cells by Dengue virus causes cell maturation
and cytokine production. Journal of Immunology, 166 (3): pp. 1499-1506.
Huang C.Y.H, Butrapet S., Tsuchiya KR, Bhamarapravati N., Gubler D.1., and
Kinney RM. 2003. Dengue 2 PDK-53 Virus as a Chimeric Carrier for
Tetravalent Dengue Vaccine Development. Journal of Virology, 77 (21): p.
11436-11447.
Huang c.Y.H., Butrapet S., Pierro D.l, Chang G.l, Hunt A.R, Bhamarapravati
N., et a!. 2000. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue
Type 1 Virus as a Potential Candidate Dengue Type ] Virus Vaccine,
Journal C?fVirology, 74 (7): p. 3020-3028.
140
Inni s B.L. 1997. Antibody responses to dengue virus infection. In D.J. Gubler and
G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University
press. p. 221-243.
Jaiswal S., Khanna N., and Swaminathan S. 2003. Replication-Defective
Adenoviral Vaccine Vector for the Induction of Immune Responses to
Denf,>ueVirus Type 2. Journal
Almond l Clemens l, Engel's H, Halstead S., Khiem HR, Pabloz-Mendez A, et
al. 2002. Accelerating the development and introduction of dengue vaccine
fool' poor children, 5-8 December 2001, Ho Chi Minh City, VietNam.
Vaccine, 20: p. 3043-3046.
Amin P., Bhandare S., and Srivastava A 2001. Dengue, Dengue Haemorrhagic
Fever,
Dengue
Shock
Syndrome.
http://www.bl1i.orQ.!journal/200I 4303 iulvOlircvicw 380.11t111
27-04-2004.
Anderson R, Wang S., Osiowy C. and Issekutz AC. 1997. Activation
Endothelial Cells via Antibody-enhanced
Dengue Virus infection
Peripheral Blood Monocytes. 1. Virol., 71 (6): p. 4226-4232.
Anna
of
of
Durbin,
Phase
I
3] 9642BSC64CBEB
http://c linicaltrials. gOY!ct{Q.ui!infilipharu~ssjonid=269
7BFAB09B4BB133, 9 ok'1ober2004).
Bancroft W.R., Top, Jr F.R., Eckels K.H, Anderson, Jr. lH, McCown lM., and
Russell P.K. 1981. Dengue-2 vaccine: virological, immunological, and
clinical responses of six yellow fever-immune recipients. l1?fect Immlln., 31
(2): p. 698-703.
Bhamarapravati N. and Y oksan S. 1997. Live attenuated tetravalent dengue
vaccine. In DJ. Gubler and G. Kune: Dengue and Dengue Hemorrhagic
Fever. Cambridge: University press. p. 367-377.
. 2000.
44-47.
Live attenuated tetravalent dengue vaccine. Vaccine, 18 (2): p.
Blaney lE. Jr, Manipon G.G., Firestone c.Y, Johnson D.H, Hanson c.T.,
Murphy RR, et al. 2003. Mutations which enhance the replication of
dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine
candidate in Vero cells. Vaccine, 21 (27-30): p. 4317-27.
Blaney Jr lE., Johnson D.H, Firestone c.Y, Hanson C.T., Murphy B.R, and
Whitehead S.S. 2001. Chemical Mutagenesis of Dengue Virus Type
4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or
Human Liver Cells and Attenuated in Mice. Journal of Virology, 75 (20): p.
9731-40.
Bosch I., Xhaja K., Estevez L., Raines G., Melichar H, Warke RY., et al. 2002.
Increased Production of Interleukin-8 in Primary Human Monocytes and in
134
135
Human Epithelial and Endothelial Cell Lines after Dengue Virus Challenge.
Journal of Virology, 76 (11): p. 5588-5597.
Bosch 1. 2003. Gene Expression of Host Cells Infected with Dengue Virus.
http://\yww.ipk .sId. cui curSO-Q~l}gUCmemoria s/confcrcncias- roam stralc s/23. pdf
,28-01-2005.
Bray M., Men R., and Lai C.I. 1996. Monkeys immunized with intertypic
chimeric dengue viruses are protected against wild-type virus challenge. J
Virol., 70 (6): p. 4162-4166.
Bumi c., Rantam F.A, Soegijanto S., dan Hamid 1.S. 2004. Determinan virulensi
virus dengue. In Soegeng Soegijanto: Demam berdarah dengue: tiryauan
OOn temuan bam di era 2003. Surabaya: Airlangga University Press. p. 9197.
Catteau A, Roue G., Yuste V.I., Susin S.A, and Despres P. 2003. Expression of
dengue ApoptoM sequence results in disruption of mitochondrial potential
and caspase activation. Biochimie, 85 (8): pp. 789-793.
CDS.1999. Regional guidenesson Dengue/DHF prevention
http://ww\v.org/whosea/cds!index.htl11 , 13-] 0-2004.
and
control.
Cella M., Salio M., Sakakibara Y, Langen R., Julkllnen 1., and Lanzavecchia A
1999. Maturation, activation, and protection of dendritic cells induced by
double stranded RNA J Exp. Med, 189 (5): p. 821-829.
Chambers T.I., Liang Y, Droll D.A, Schlesinger J.J, Davidson AD., Wright PJ.,
et al. 2003. Yellow Fever Virus/Dengue-2
Virus and Yellow Fever
Virus/Dengue-4
Virus
Chimeras:
Biological
Characterization,
Immunogenicity, and Protection against Dengue Encephalitis in the Mouse
Model. Journal of Virology, 77 (6): p. 3655-3668.
Chang D.M. and Shaio M.F.1994. Production of interleukin-l (lL-l) and lL-l
inhibitor by human monocytes exposed to dengue virus. Journal of
Infectious Diseases, 170 (4): pp. 811-817.
Chang G.J. 1997. Molecular biology of dengue viruses. In DJ. Gubler and G.
Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University
press. p. 175-198.
Chang G.I., Kuno G., Purdy D.E., and Davis B.S. 2004. Recent advancement
flavivirus vaccine development. Expert Rev 'Vaccines., 3 (2): p. 199-220.
in
Chang HH., Shyu H.F., Wang YM., Sun D.S., Shyu RH, Tang S.S., et al. 2002.
Facilitation of cell adhesion by immobilized dengue viral non structural
136
protein 1 (NS1): Arginine-glycine-aspartic acid structural mimicry within
the dengue viral NS 1 antigen. Journal of ltifectious Diseases, ] 86 (6): pp.
743-751.
Chao D.Y, Lin T.H., Hwang KP., Huang J.H., Liu c.c., and King C.C.1998.
dengue
hemoIThagic
fever
epidemic
in
Taiwan.
L/'iDV\\'..~d_~£QyincidO(EEfJ)Iy_ol1 Ono3/0_~::(L'J_~htm,
27-04-2004.
Chaturvedi u.c., Elbishbishi E.A, Agarwal R, and Mustafa AS. 2001. Cytotoxic
factor-autoantibodies: possible role in the pathogenesis of dengue
haemorrhagic fever FEMS. Immunology & Medical Microbiology, 30 (3):
pp. 181-186.
Chen yc. and Wang S.Y 2002. Activation of Terminally Differentiated Human
Monocytes/Macrophages
by Dengue Virus: Productive Infection,
Hierarchical Production of Innate Cytokines and Chemokines, and the
Synergistic Effect of Lipopolysaccharide. Journal of Virology, 76 (19): p.
9877-9887.
Chen YP., Maguire T., Hileman RE., Fromm J.R, Esko J.D., Linhardt RJ. et a1.
1997. Dengue virus infectivity depends on envelope protein binding to target
cel1 heparan sulfate. Nature Medicine, 3 (8): p. 866-871.
Chung N.P.Y, Chen Y, Chan V.S.F., TAM P.KH., and Lin c.L.S. 2004.
Dendritic cells: sentinels against pathogens. Histology and Histopathology,
]9 (1): p. 317-314.
Chungue E., Poli L., Roche c., Gestas P., Glaziou P., and Markoff LJ. 1994.
Correlation between detection of plasminogen cross-reactive antibodies and
hemorrhage in dengue virus infection. J l1ifect Dis., 170 (5): p. ] 304-7.
Craig S., Myat Thu H., Lowry K, Wang x.F., Holmes E.C., and Aaskov J. 2003.
Diverse dengue type 2 virus population contain recombinant and both
parental viruses in a single mosqiuto host. Journal of T'irology, 77 (7): p.
4463-4467.
Diamond M.S., Edgil D., Roberts T.G., Lu B., and Harris E. 2000. Infection of
Human Cel1s by Dengue Virus Is Modulated by Different Cel1 Types and
Viral Strains. Journal ofTTirology, 74 (17): p. 7814-7823.
Dos Santos F.B., Miagostovich M.P., Noguiera M.R, Schatmayr H.G., Riley
L.W., Harris E. Analysis of recombinant Dengue virus polypeptides for
Dengue diagnosis ang evaluation of the humoral immune response. Am. 1.
Trop. A1ed. Hyg., 71(2): pp. ]44-]52
137
Durbin AP., Karron RA, Sun W., Vaughn D.W., Reynolds M.l, Perreault lR,
et aI. 200]. Attenuation and Immunogenecity in Humans of Live Dengue
Virus type-4 Vaccine Candidate with 30 Nucleotide Deletion in its 3'Untranslated Region. Am. J Trop. Med. Hyg., 65 (5): p. 405-413.
Eckels KH. and Putnak R 2003. Formalin-inactivated whole virus and
recombinant subunit flavivirus vaccines. Adv Vims Res, 61: p. 395-418.
Eckels KH., Scott RM., Bancroft W.H., Brown l, Dubois D.R, Summers P.L.,
et al. ] 984. Selection of attenuated dengue 4 viruses by serial passage in
primary kidney cells. V. Human response to immunization with a candidate
vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg., 33 (4): p.
684-9.
Edelman R, Wasserman S.S., Bodison S.A, Putnak R.l, Eckels KH., Tang D., et
al. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated
dengue vaccine. Am J TropMed Hyg., ;69(6 Suppl):48-60.
Espina L.M., Valero N.J., Hernandez lM., and Mosquera lA 2003. Increased
apoptosis and expresion of tumor necrosis factor a caused by infection of
cultured of human monocytes with dengue virus. Am. J Trop. Med. Hyg., 68
(1): p. 48-53.
Gagnon S.J., Ennis F.A, and Rothman AL. ]999. Bystander Target Cell Lysis
and Cytokine Production by Dengue Virus-Specific Human CDr Cytotoxic
T-Lymphocyte Clones. Journal of Virology, 73 (5): p. 3623-3629.
Gagnon S.J., Mori M., Kurane I., Green S., Vaughn D.W., Kalayanarooj S., et al.
2002. Cytokine gene expression and protein production in peripheral blood
mononuclear cells of children with acute dengue virus infections. J Med
Virol, 67 (1): p. 4]-6.
Green
S., Vaughn D.W., Kalayanarooj S., Nimmannitya
S., Suntayakorn S.,
]
Nisalak A, et al. 999. Early Immune Activation in Acute Dengue Illness Is
Related to Development
of Plasma Leakage and Disease Severity.
The Journal
£?!Infectious
Diseas'es,
] 79: p. 755-762.
Green S., Kurane I., Edelman R, Tacket CO, Eckels KH., Vaughn D.W., Hoke
Jr CH., and Ennis F.A 1993. Dengue virus-specific human CD4+ Tlymphocyte responses in a recipient of an experimental live-attenuated
dengue virus type ] vaccine: bulk culture proliferation, clonal analysis, and
precursor frequency determination. J Virol., 67 (10): p. 5962-67.
Gubler D.J. 1998. Dengue and dengue hemorrhagic fever. Clinical Microbiology
Reviews, 11(3): p. 480-496.
138
Guirakhoo F., Arroyo 1., Pugachev KY., Miller c., Zhang Z.X, Weltzin R, et al.
2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of a
Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. Journal of
Virology, 75 (16): p. 7290-7304.
Guirakhoo F., Pugachev K, Arroyo 1., Miller c., Zhang Z.X, Weltzin R, et al.
2002. Viremia and immunogenicity in nonhuman primates of a tetravalent
yellow fever-denbrue chimeric vaccine: genetic reconstructions, dose
adjustment, and antibody responses against wild-type dengue virus isolates.
Virology, 298 (1): p. 146-59.
Guirakhoo F., Pugachev K, Zhang Z., Myers G., Levenbook 1., Draper K,et aI.
2004.
Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus
Tetravalent Vaccine Formulations
in Nonhuman Primates. Journal qf
Virology, 78 (9): p. 4761-4775
Guirakhoo
F., Weltzin R, Chambers TJ., Zhang Z.X,
Soike K, Ratterree M.,.
Arroyo 1., et aI. 2000. Recombinant Chimeric Yellow Fever-Dengue Type
2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal of
Virology, 74 (12): p. 5477-5485.
Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K, Nichols
2004. A single amino acid substitution in the envelope protein of
yellow fever-dengue 1 vaccine virus reduces neurovirulence for
mice and viremia/viscerotropism
for monkeys. J Virol., 78 (18):
10008.
Guzman M.G. 1998. Advances in the development
Acta Cient Venez., 49 Suppl 1: p. 38-45
R, et aI.
chimeric
suckling
p. 9998-
of a vaccine against dengue.
Guzman M.G., Rodriguez R, Rodriguez R, Hennida L., Alvarez M., Lazo L., et
aI. 2003. Induction of neutralizing antibodies and partial protection fron viral
challengge in Macaca Fascicularis immunized with recombinant Dengue 4
virus envelope gycoprotein expressed in Pischia pastoris .Am. 1. Trap. Med
Hyg., 69 (2): p. 129-134.
Gwinn W., Sun W., Innis B.L., Caudill 1., and King AD. 2003. Serotype-specific
TH1 responses in recipients of two doses of candidate live-attenuated
dengue virus vaccines. American Journal of Tropical Medicine & Hygiene,
69 (6): p. 39-47 (SuppI. S).
Hadinegoro
A,RH.,
Soegijanto S., Wuryahadi S., dan Suroso T. 1998.
Tatalaksana demam dengue/demam berdarah dengue pada anak. In Sri
Rezeki H. Hadinegoro dan Hindra Irawan Satari: Demam berdarah dengue.
Jakarta: FKUI. p. 82-84.
139
Halstead S.B. 1988. Pathogenesis of dengue: challenges to molecular biology.
Science, 239 (4839): p. 476-81.
Halstead S.B. 1997. Epidemiology of dengue and dengue hemorrhagic fever. In
D.1. Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever.
Cambridge: University press. p. 23-44.
Halstead S.B. and Marchette N.1. 2003. Biologic properties of dengue viruses
following serial passage in primary dog kidney cells: Studies at the
University of Hawaii. American Journal of Tropical Medicine & Hygiene,
69 (6): pp. 5-11 (Supp!. S).
Hanley KA., Manlucu L.R, Manipon G.G., Hanson C.T., Whitehead S.S.,
Murphy B.R, et a!. 2004. Introduction of mutations into the non-structural
genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine
candidate further decreases replication in rhesus monkeys while retaining
protective immunity. Vaccine, 22 (25-26): p. 3440-8.
Hanley KA., Lee J.1., Blaney, Jr lE., Murphy B.R., and Whitehead S.S. 2002.
Paired Charge-to-Alanine
Mutagenesis of Dengue Virus Type 4 NS5
Generates Mutants with Temperature-Sensitive,
Host Range, and Mouse
Attenuation Phenotypes. Journal (if Virology, 76 (2): p. 525-531.
Harrison V.R, Eckels KH., Sagartz lW., and Russell P.K 1977. Virulence and
immunogenicity of a temperature-sensitive dengue-2 virus in lower
primates. Infect Immull.,18 (1): p. 151-6.
Henke A. 2002. DNA immunization--a new chance in vaccine research? Med
A1icrobiollmmunol (Berl)., 191 (3-4): p. 187-90.
Ho L.1., Wang J.1., Shaio M.F., Kao c.L., Chang D.M., Han S.W., et a!. 2001.
Infection of human dendritic cells by Dengue virus causes cell maturation
and cytokine production. Journal of Immunology, 166 (3): pp. 1499-1506.
Huang C.Y.H, Butrapet S., Tsuchiya KR, Bhamarapravati N., Gubler D.1., and
Kinney RM. 2003. Dengue 2 PDK-53 Virus as a Chimeric Carrier for
Tetravalent Dengue Vaccine Development. Journal of Virology, 77 (21): p.
11436-11447.
Huang c.Y.H., Butrapet S., Pierro D.l, Chang G.l, Hunt A.R, Bhamarapravati
N., et a!. 2000. Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue
Type 1 Virus as a Potential Candidate Dengue Type ] Virus Vaccine,
Journal C?fVirology, 74 (7): p. 3020-3028.
140
Inni s B.L. 1997. Antibody responses to dengue virus infection. In D.J. Gubler and
G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University
press. p. 221-243.
Jaiswal S., Khanna N., and Swaminathan S. 2003. Replication-Defective
Adenoviral Vaccine Vector for the Induction of Immune Responses to
Denf,>ueVirus Type 2. Journal